



## Placement Fully Funds Completion of XanADu Alzheimer's Trial

- Successful oversubscribed placement raises \$5.28 million
- Placement fully funds the completion of XanADu, Actinogen's Phase II trial of Xanamem™ in Alzheimer's disease
- Interim XanADu efficacy and safety analysis planned for April-June 2018
- Data available one year earlier than full study results
- XanADu clinical trial on track for top-line results in April-June 2019

**Sydney, 29 November 2017: Actinogen Medical, (Actinogen) (ASX: ACW)** is pleased to announce that it has successfully raised \$5.28 million through a placement to sophisticated investors.

The funds were raised via subscriptions for 132,000,000 fully paid ordinary shares at \$0.04 per share (**Placement**), representing a discount of 21.9% on the 15-day volume weighted average price (VWAP) prior to the Placement.

Proceeds from the Placement fully funds the completion of XanADu, Actinogen's Phase II trial of Xanamem in Alzheimer's disease. There are currently 44 patients enrolled in the trial with 6 patients having already completed the trial. Actinogen remains on track to enrol the 174<sup>th</sup> and final patient by the end of 2018, with top-line results due in April-June 2019.

Importantly, Actinogen also announced today that an interim efficacy and safety analysis will be conducted on the first 50 patients to complete the XanADu trial and data will be available in April-June 2018, one year earlier than the full study results.

Actinogen Medical CEO Dr Bill Ketelbey said: "Completion of the XanADu trial will provide the definitive proof of Xanamem's effectiveness in Alzheimer's disease and this Placement means we are fully funded through to completion of the trial in 2019. Notably, interim efficacy and safety data on XanADu will be available in April - June 2018, a year before the full trial completes. On behalf of Actinogen Medical, I would like to thank all investors who participated in the Placement and we look forward to providing updates on the progress of XanADu and Xanamem's development in the months ahead."

**Details of the Placement:** \$3.66 million will be raised through the issue of 91.5m shares (**Tranche 1 Placement Shares**) under the Company's 15% placement capacity on 8 December 2017. The issue of the additional 40.5m shares (**Tranche 2 Placement Shares**) will raise \$1.62m and is subject to shareholder approval. All Placement shares will be entitled to free attaching options on a 1:2 basis exercisable at \$0.06 each on or before 31 March 2019 (**Placement Options**). The issue of the Placement Options will be made under a prospectus, and is subject to shareholder approval at a general meeting of the Company to be held in January 2018.

Additionally, existing shareholders at close of trading on 7 December (Record Date), with a residential address in Australia or New Zealand, will receive 2:15 free loyalty bonus options, on the same terms as the Placement Options (**Loyalty Options**). Application will be made to the ASX to list the Placement Options and Loyalty Options. Participants in the Placement will not be entitled to receive the Loyalty Options.

Forrest Capital acted as Lead Manager to the Placement.

## Placement and Loyalty Option Offer Timetable

The dates provided in the timetable below are indicative only and are subject to change at the Company's complete discretion.

Placement announced, and Company's shares re-commence trading on the ASX	Wednesday, 29 November 2017
Lodgement of Prospectus for the offer of the Loyalty Options and the Placement Options with ASIC	Friday, 1 December 2017
Existing shares quoted on an "ex" basis	Wednesday, 6 December 2017
Record Date for determining shareholders entitled to participate in the Loyalty Option issue	Thursday, 7 December 2017
Settlement and issue of Tranche 1 Placement Shares	Friday, 8 December 2017
Anticipated date for the issue of the Loyalty Options	On or before 21 December 2017
General Meeting to approve the issue of the Tranche 2 Placement Shares and the Placement Options	January 2018
Anticipated date for settlement and issue of the Tranche 2 Placement Shares and issue of the Placement Options	January 2018

**ENDS**

### Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### Media Enquiries

Caroline Zielinski

Media & Capital Partners

M: +61 400 172 145

E: [caroline.zielinski@mcpartners.com.au](mailto:caroline.zielinski@mcpartners.com.au)

## About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

## About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that

**ACTINOGEN MEDICAL LIMITED** TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB [www.actinogen.com.au](http://www.actinogen.com.au)

leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**